Shilpa Medicare Makes History: First Indian Company Completes Phase 1 Trial for Recombinant Human Albumin (rHA) 20 per cent
Aug 28, 2024
Raichur (Karnataka) [India], August 28: In a major breakthrough, Shilpa Medicare Limited (BSE: 530549) (NSE: SHILPAMED) proudly announces the successful completion of its Phase 1 clinical trial for its flagship product, sRbumin® - recombinant human albumin® 20% (rHA), becoming the first Indian company to achieve this milestone. The positive results underscore rHA's potential as a viable alternative to plasma-derived human serum albumin, addressing a critical gap in global healthcare.
Read More ..
